Compound and method for the treatment and diagnosis of neurodegenerative conditions
US10226475B2 · kind B2 · utility
0Cited by
1References
6Claims
0Family size
Assignee
Inventors
Key dates
| Filing date | Feb 26, 2014 |
| Grant date | Mar 12, 2019 |
| Priority date | — |
| Expiry date | Feb 26, 2034 |
Classification
- Technology area (CPC G)Physics
- CPC primaryG01N2800/28
- WIPO fieldPharmaceuticals
- WIPO sectorChemistry
Abstract
A reagent selected from cholestenoic acid or an inhibitor of an enzyme in the cholestenoic acid biosynthetic or metabolic pathway for use in the treatment of neurodegenerative conditions. In particular, the reagent is a cholestenoic acid of a particular form, such as 3β,7α-dihydroxycholest-5-en-26-oic (3β,7α-diHCA), not previously associated with neural tissue or CSF. Pharmaceutical compositions, methods of treatment or prevention of neurodegenerative conditions as well as diagnostic methods and novel biomarkers form further aspects of the invention.
Source: USPTO / EPO open patent data. Objective bibliographic and citation counts.